Vise Technologies Inc. Takes $743,000 Position in Halozyme Therapeutics, Inc. $HALO

Vise Technologies Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,499 shares of the biopharmaceutical company's stock, valued at approximately $743,000.

A number of other hedge funds have also bought and sold shares of HALO. Measured Wealth Private Client Group LLC raised its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 343 shares in the last quarter. MidFirst Bank bought a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $28,000. Finally, Harbour Investments Inc. raised its position in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 372 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $108.17 on Monday. The firm has a 50 day moving average of $83.19 and a 200-day moving average of $73.74. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $108.49. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $12.28 billion, a PE ratio of 32.29, a PEG ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several recent research reports. Citizens Jmp boosted their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Weiss Ratings cut Halozyme Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, August 14th. TD Cowen upped their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock worth $5,226,496 over the last three months. Insiders own 2.50% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source